Alectinib + Crizotinib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Conditions
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Trial Timeline
Aug 3, 2016 → Jun 30, 2026
NCT ID
NCT02838420About Alectinib + Crizotinib
Alectinib + Crizotinib is a phase 3 stage product being developed by Roche for Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02838420. Target conditions include Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03194893 | Phase 3 | Active |
| NCT02838420 | Phase 3 | Active |
| NCT02075840 | Phase 3 | Completed |
Competing Products
20 competing products in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | 41 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| LDK378 + AUY922 | Novartis | Phase 1 | 33 |
| ceritinib | Novartis | Pre-clinical | 23 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Cemiplimab + XL092 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Etirinotecan pegol | Nektar Therapeutics | Phase 2 | 47 |
| Bevacizumab | Novocure | Phase 2 | 47 |